Profitability is strengthened by cost savings, while sales growth remains sluggish.
Pfizer's adjusted earnings per share will be $3.00-$3.15, according to the revised forecast. Previously, the upper limit of Pfizer's earnings forecast was $3.10.
However, the sales forecast is left unchanged at $61-64 billion.
Pfizer is currently in a bidding war with Denmark's Novo Nordisk. Both pharmaceutical companies want to buy the American biotechnology company Metsera, which develops weight-loss drugs that the combatants want to get their hands on.
